Last reviewed · How we verify
Jan Franko, MD — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| SuperBio probiotic | SuperBio probiotic | phase 3 | Probiotic | Gastroenterology |
Therapeutic area mix
- Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- BioBalance Corporation · 1 shared drug class
- Biocodex · 1 shared drug class
- CD Pharma India Pvt. Ltd. · 1 shared drug class
- CHU de Quebec-Universite Laval · 1 shared drug class
- Chuncheon Sacred Heart Hospital · 1 shared drug class
- Dow University of Health Sciences · 1 shared drug class
- Federico II University · 1 shared drug class
- Aga Khan University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Jan Franko, MD:
- Jan Franko, MD pipeline updates — RSS
- Jan Franko, MD pipeline updates — Atom
- Jan Franko, MD pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Jan Franko, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jan-franko-md. Accessed 2026-06-09.